AMAG Pharmaceuticals, Inc.  

(Public, NASDAQ:AMAG)   Watch this stock  
Find more results for AMAG
-0.23 (-0.33%)
Jul 2 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 69.80 - 71.62
52 week 17.79 - 74.21
Open 70.86
Vol / Avg. 352,915.00/703,931.00
Mkt cap 2.16B
P/E 16.03
Div/yield     -
EPS 4.40
Shares 30.53M
Beta 0.21
Inst. own 130%
Jul 27, 2015
Q2 2015 AMAG Pharmaceuticals Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Jun 29, 2015
AMAG Pharmaceuticals, Inc. to Acquire Cord Blood Registry M&A Call - Webcast
Jun 11, 2015
AMAG Pharmaceuticals Inc at Barclays High Yield Bond & Syndicated Loan Conference
Jun 3, 2015
AMAG Pharmaceuticals Inc at Jefferies Global Healthcare Conference
May 21, 2015
AMAG Pharmaceuticals Inc Annual Shareholders Meeting
May 18, 2015
AMAG Pharmaceuticals Inc at UBS Global Healthcare Conference
May 7, 2015
AMAG Pharmaceuticals Inc at Robert W. Baird & Co. Inc's Growth Stock Conference
May 6, 2015
AMAG Pharmaceuticals Inc at Deutsche Bank Health Care Conference - Webcast
May 5, 2015
Q1 2015 AMAG Pharmaceuticals Inc Earnings Release
May 5, 2015
Q1 2015 AMAG Pharmaceuticals Inc Earnings Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin 14.42% 109.19%
Operating margin 32.19% -3.08%
EBITD margin - 11.78%
Return on average assets 3.44% 16.42%
Return on average equity 9.15% 42.96%
Employees 257 -
CDP Score - -


1100 Winter St
WALTHAM, MA 02451-1427
United States - Map
+1-617-4983300 (Phone)
+1-617-4993361 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


AMAG Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company focuses on maternal health, anemia and cancer supportive care. The Company markets Makena (hydroxyprogesterone caproate injection), Feraheme (ferumoxytol) Injection for Intravenous (IV) use and MuGard Mucoadhesive Oral Wound Rinse. Feraheme is an IV iron replacement therapy for the treatment of iron deficiency anemia (IDA) in adult patients with chronic kidney disease (CKD). Feraheme is approved for marketing in the United States. Makena is a drug indicated to reduce the risk of preterm birth in women with a singleton pregnancy who have a history of singleton spontaneous preterm birth. MuGard is indicated for the management of oral mucositis/stomatitis and all types of oral wounds, including aphthous ulcers/canker sores and traumatic ulcers, such as those caused by oral surgery or ill-fitting dentures or braces.

Officers and directors

Gino Santini Chairman of the Board
Age: 58
Bio & Compensation  - Reuters
Frank E. Thomas President, Interim Principal Financial Officer, Chief Operating Officer, Interim Principal Accounting Officer
Age: 45
Bio & Compensation  - Reuters
William K. Heiden Chief Executive Officer, Director
Age: 55
Bio & Compensation  - Reuters
Scott A. Holmes Senior Vice President - Finance and Investor Relations, Chief Accounting Officer, Treasurer
Age: 40
Bio & Compensation  - Reuters
Scott B. Townsend Esq. Senior Vice President - Legal Affairs, General Counsel, Secretary
Age: 46
Bio & Compensation  - Reuters
Edward Jordan Senior Vice President - Sales and Marketing
Age: 47
Bio & Compensation  - Reuters
Linda Lennox Vice President of Investor Relations, & Corporate Communications
Bio & Compensation  - Reuters
Katie Payne Vice President - External Affairs.
Bio & Compensation  - Reuters
Aaron Pelta Vice President - Business Development
Bio & Compensation  - Reuters
John A. Fallon Director
Age: 67
Bio & Compensation  - Reuters